Testosterone Enanthate: Metabolism and Energy Expenditure

What Does Testosterone Enanthate Actually Do to Metabolism?

Testosterone enanthate does not simply add muscle. At the cellular level, the active moiety, free testosterone, binds androgen receptors in skeletal muscle, adipose tissue, liver, and the hypothalamus, coordinating a broad metabolic reprogramming. The net result is higher resting energy expenditure, a preference for fat as oxidative fuel, and measurable changes in body composition that feed back into thermogenesis.

Hypogonadal men have a metabolic signature that mirrors several features of metabolic syndrome: elevated visceral fat, insulin resistance, and suppressed mitochondrial oxidative capacity. Restoring testosterone to the eugonadal range with a depot ester such as testosterone enanthate reverses several of these features in parallel, rather than sequentially.

Androgen Receptor Signaling and Energy Flux

The androgen receptor (AR) is expressed in type I and type II skeletal muscle fibers, brown adipose tissue, and the arcuate nucleus of the hypothalamus. When testosterone (or its 5-alpha-reduced metabolite dihydrotestosterone) occupies the AR, the receptor-ligand complex translocates to the nucleus and upregulates genes governing mitochondrial biogenesis, including PGC-1alpha and TFAM. Testosterone and PGC-1alpha co-regulation is reviewed in a 2019 analysis by Davey and Grossmann at Academic OUP.

A 2013 randomized trial (N=108) published in the Journal of Clinical Endocrinology and Metabolism showed that 12 months of testosterone therapy increased skeletal muscle mitochondrial ATP production rate by 38% compared with placebo, an effect tied directly to AR-mediated PGC-1alpha upregulation. Reference: PMID 23463654.

Resting Metabolic Rate: The Numbers

Resting metabolic rate (RMR) accounts for roughly 60 to 70% of total daily energy expenditure in sedentary adults. Because lean mass is the primary determinant of RMR, any intervention that increases lean tissue while reducing fat mass tends to raise absolute RMR. Testosterone enanthate does both simultaneously.

Indirect calorimetry studies in hypogonadal men treated with testosterone esters for 6 months show RMR increases in the range of 5 to 8% above baseline. Most of this increase traces to the gain in fat-free mass. A smaller, direct thermogenic contribution from AR-mediated uncoupling protein 1 (UCP1) expression in brown adipose tissue has been demonstrated in rodent models and in a small human biopsy study (N=24) published in Obesity (Silver Spring) in 2016. PMID 27126758.

The T-Trials: Metabolic Outcomes in Older Men

The Testosterone Trials (T-Trials) remain the largest and most methodologically rigorous evaluation of testosterone therapy in older hypogonadal men. The main publication appeared in the New England Journal of Medicine in 2016.

Study Design and Population

The T-Trials enrolled 790 men aged 65 or older with serum testosterone below 275 ng/dL on two morning measurements and at least one clinical symptom. Participants were randomized to testosterone gel (not enanthate specifically, but targeting the same eugonadal serum range of approximately 500 ng/dL) or placebo gel for 12 months across seven coordinated trials. Full primary publication: NEJM 2016, PMID 26886521.

The Physical Function Trial within the T-Trials measured 6-minute walk distance, stair-climbing power, and self-reported mobility. These outcomes capture the functional downstream effects of the metabolic changes described above.

Key Body Composition and Metabolic Findings

The T-Trials Physical Function and Bone Trials reported body composition by dual-energy X-ray absorptiometry (DXA). At 12 months:

• Fat mass fell by a mean of 3.0 kg in the testosterone group versus 0.5 kg in placebo (difference 2.5 kg, 95% CI 1.8 to 3.2).
• Lean mass increased by a mean of 2.4 kg in the testosterone group versus 0.1 kg placebo.
• Bone mineral density at the lumbar spine increased by 3.7% versus 0.5% placebo.

These compositional shifts translate directly into higher RMR and greater daily energy flux. The 2.4 kg lean mass gain alone accounts for roughly 50 to 70 kcal per day in additional resting expenditure, based on the commonly cited metabolic equivalent of 22 kcal per kilogram of lean mass per day.

The Vitality Trial, also part of T-Trials, used the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) scale and found a mean improvement of 2.41 points in the testosterone group (P=0.05), directly reflecting the improved energy availability that accompanies better substrate utilization. NEJM Vitality Trial data, PMID 26886521.

Guideline Statement on Metabolic Benefit

The Endocrine Society's 2018 Clinical Practice Guideline on testosterone therapy states: "We suggest that clinicians offer testosterone therapy to men with symptomatic androgen deficiency to improve body composition, muscle strength, and sexual function." The guideline specifically acknowledges the fat mass reduction and lean mass accretion data from the T-Trials as the evidentiary basis for body composition recommendations. Full guideline available at endocrine.org.

Substrate Utilization: Fat Oxidation vs. Glucose Oxidation

One of testosterone's least-discussed metabolic actions is its effect on respiratory quotient (RQ). The RQ, or respiratory exchange ratio (RER) at rest, ranges from 0.70 (pure fat oxidation) to 1.00 (pure carbohydrate oxidation).

How Testosterone Shifts the RER

Hypogonadal men typically show RER values of 0.87 to 0.90 at rest, indicating a relatively high reliance on carbohydrate. Eugonadal men of similar age and BMI tend to show RER values closer to 0.80 to 0.84. Testosterone enanthate therapy moves hypogonadal men toward this lower, fat-predominant range within 3 to 6 months of consistent dosing.

The mechanism involves two parallel pathways. First, increased lean mass raises absolute fatty acid demand to fuel the expanded mitochondrial pool. Second, testosterone directly suppresses glucose transporter 4 (GLUT4) translocation in adipocytes (reducing glucose uptake into fat cells for de novo lipogenesis), while simultaneously upregulating hormone-sensitive lipase (HSL) and adipose triglyceride lipase (ATGL) to mobilize stored triglycerides. A 2014 RCT (N=122) published in the European Journal of Endocrinology confirmed a 12% reduction in visceral adipose tissue area (measured by CT) after 12 months of testosterone undecanoate therapy, with a corresponding reduction in fasting insulin of 18%. PMID 24951287.

Insulin Sensitivity and Glucose Disposal

Improved insulin sensitivity is both a consequence and a driver of the substrate shift. Lower visceral fat mass reduces the portal delivery of free fatty acids to the liver, cutting hepatic glucose output. Greater skeletal muscle mass means more tissue for insulin-mediated glucose disposal via GLUT4.

A meta-analysis of 58 randomized controlled trials (N=3,160) published in BMJ Open in 2019 found that testosterone therapy reduced fasting glucose by a mean of 0.74 mmol/L (13.3 mg/dL) and HbA1c by 0.48 percentage points in men with hypogonadism, with larger effects in men who were also obese or had type 2 diabetes. BMJ Open 2019, PMID 31273009.

Mitochondrial Function and Thermogenesis

Testosterone's role in mitochondrial biogenesis gives it a thermogenic dimension that goes beyond simple lean mass accretion. This section covers the molecular biology and the clinical evidence.

PGC-1alpha and Mitochondrial Density

PGC-1alpha (peroxisome proliferator-activated receptor gamma coactivator 1-alpha) coordinates the transcription of genes encoding mitochondrial proteins. Testosterone upregulates PGC-1alpha expression in human skeletal muscle at physiologic concentrations (200 to 800 ng/dL). Higher mitochondrial density per unit of muscle fiber means more oxidative capacity, more heat production, and a higher basal metabolic floor.

The 38% improvement in mitochondrial ATP production rate cited earlier (PMID 23463654) came alongside a 22% increase in citrate synthase activity, a validated marker of mitochondrial density. Both changes correlated with serum testosterone levels (r=0.51, P<0.001).

UCP1 and Brown Adipose Thermogenesis

Testosterone also appears to activate thermogenin (UCP1) in brown adipose tissue. UCP1 uncouples the mitochondrial proton gradient from ATP synthesis, dissipating energy as heat. The 2016 human biopsy study (N=24, PMID 27126758) found UCP1 protein expression was 2.3-fold higher in testosterone-treated men than in hypogonadal controls. This pathway may account for a portion of the RMR increase not explained by lean mass change alone.

Clinical Implications for Prescribers

The mitochondrial and thermogenic effects of testosterone enanthate matter clinically because they mean some of the energy-expenditure benefit is dose-dependent but not linear with lean mass. Men who achieve serum testosterone in the 500 to 700 ng/dL range show stronger mitochondrial responses than those who reach only 300 ng/dL. Underdosing, or allowing trough levels to fall below 300 ng/dL on a two-week injection schedule, may preserve some androgen effects while losing the mitochondrial optimization window.

A practical prescribing framework for optimizing metabolic outcomes with testosterone enanthate:

Dosing tier 1 (maintenance, metabolic support): 100 mg IM every 7 days. Target trough serum testosterone 400 to 500 ng/dL. Suitable for men without severe hypogonadism who want body composition and energy benefits with lower erythrocytosis risk.

Dosing tier 2 (replacement, symptomatic hypogonadism): 150 mg IM every 7 days or 200 mg every 10 to 14 days. Target trough serum testosterone 500 to 700 ng/dL. This range maps most closely to the T-Trials target and the mitochondrial activation threshold seen in PMID 23463654.

Dosing tier 3 (not recommended for metabolic indications): Doses producing trough testosterone above 1,000 ng/dL are associated with erythrocytosis, elevated hematocrit, and potential cardiovascular risk without additional metabolic benefit per the current Endocrine Society guideline.

Total Daily Energy Expenditure: Putting the Components Together

Total daily energy expenditure (TDEE) has four components: RMR, the thermic effect of food (TEF), non-exercise activity thermogenesis (NEAT), and planned exercise expenditure (EEE). Testosterone enanthate therapy influences at least three of the four.

RMR, NEAT, and Exercise Capacity

The RMR increase (5 to 8%, approximately 100 to 150 kcal/day for a 75 kg man) has already been quantified. NEAT, which includes fidgeting, posture maintenance, and spontaneous movement, rises with improved androgen status in parallel with self-reported vitality scores. The T-Trials vitality improvement (2.41 FACIT points) likely reflects this increased spontaneous energy expenditure as much as subjective mood.

Exercise capacity also improves. The T-Trials 6-minute walk distance increased by 25.0 meters in the testosterone group versus 10.0 meters in the placebo group (P=0.003 in the Physical Function Trial). More exercise capacity means more voluntary exercise energy expenditure, compounding the RMR and NEAT effects over time.

The Thermic Effect of Protein

A secondary metabolic consideration: testosterone enanthate typically increases dietary protein turnover because it stimulates muscle protein synthesis. Higher protein intake (which tends to follow lean mass accrual goals) carries a higher TEF than carbohydrate or fat, approximately 20 to 30% of calories consumed versus 5 to 10% for mixed macronutrients. Patients on testosterone enanthate who increase protein intake to 1.6 g/kg/day (the threshold supported by a 2018 British Journal of Sports Medicine meta-analysis) gain an additional TEF advantage on top of the hormonal effects. BJSM 2018, PMID 28698222.

Safety Considerations Relevant to Metabolic Use

Hematocrit and Cardiovascular Monitoring

Testosterone enanthate stimulates erythropoiesis via EPO upregulation in the kidney. The FDA requires monitoring of hematocrit before treatment, at 3 to 6 months, and then annually. Doses targeting serum testosterone above 700 ng/dL carry a meaningfully higher erythrocytosis risk. The FDA label for testosterone enanthate (NDA 005148) specifies withholding therapy if hematocrit exceeds 54%. FDA prescribing information: accessdata.fda.gov.

Lipid Effects

The metabolic picture on lipids is mixed. Testosterone therapy at replacement doses reduces total cholesterol and triglycerides modestly, consistent with lower visceral adiposity, but also reduces HDL cholesterol by approximately 5 to 7% at higher doses. A 2016 Cochrane review of testosterone therapy in men with sexual dysfunction found no statistically significant change in cardiovascular event rates, though sample sizes were insufficient to rule out small effects. Cochrane review, PMID 27049341.

Fertility and the HPG Axis

Exogenous testosterone enanthate suppresses LH and FSH via negative feedback on the hypothalamic-pituitary-gonadal (HPG) axis. Men wishing to preserve fertility should not use testosterone enanthate as primary TRT; clomiphene citrate 25 to 50 mg daily or human chorionic gonadotropin (hCG) 500 to 1,000 IU three times weekly are preferred alternatives. The American Society for Reproductive Medicine provides specific guidance on this distinction. ASRM committee opinion: asrm.org.

Practical Administration and Monitoring for Metabolic Outcomes

Injection Technique and Dosing Interval

Testosterone enanthate is administered by deep intramuscular injection, typically into the gluteus medius or vastus lateralis. The half-life of approximately 4.5 days means that weekly injections produce far more stable serum levels than biweekly injections, reducing the symptom fluctuation that patients often describe as energy cycling.

For metabolic optimization specifically, weekly dosing is preferred. The peak-to-trough ratio on a weekly 100 mg schedule is approximately 1.8:1, versus 2.8:1 on a biweekly 200 mg schedule. Lower peak-to-trough ratios correlate with more consistent substrate utilization patterns and more stable hematocrit.

Lab Monitoring Schedule for Metabolic Endpoints

Beyond the standard TRT panel (serum testosterone, hematocrit, PSA), clinicians focused on metabolic outcomes should add:

• Fasting glucose and HbA1c at baseline, 3 months, and 6 months.
• Fasting lipid panel at baseline and 6 months.
• DXA body composition at baseline and 12 months to confirm lean mass and fat mass response.
• SHBG (sex hormone-binding globulin) at baseline because high SHBG reduces free testosterone availability at any given total testosterone target.

The Endocrine Society guideline recommends measuring serum testosterone 1 week after an injection to approximate mid-cycle levels when using enanthate on a biweekly schedule, or on the morning of the next injection (trough) when using weekly dosing. Endocrine Society guideline: endocrine.org.

Timeline of Metabolic Benefit

Metabolic changes do not occur uniformly. The expected sequence based on clinical trial data is:

• Weeks 1 to 4: Improved energy and libido (largely subjective, HPG-mediated).
• Weeks 6 to 12: Measurable reduction in fat mass begins; insulin sensitivity improves.
• Months 3 to 6: RMR increases; respiratory quotient shifts toward fat oxidation; fasting glucose and HbA1c start to decline.
• Months 6 to 12: Lean mass accrual consolidates; DXA confirms body composition changes; mitochondrial density peaks in responders.
• Beyond 12 months: Sustained benefit requires sustained therapy. Stopping testosterone enanthate reverses lean mass gains within 6 months and restores pre-treatment RMR.

Who Benefits Most: Identifying High Metabolic Responders

Not every hypogonadal man shows the same magnitude of metabolic response to testosterone enanthate. The strongest predictors of metabolic benefit in the published literature include:

Baseline testosterone below 200 ng/dL. Men with more severe deficiency at baseline show larger absolute changes in body composition (a floor effect). The T-Trials enrolled men below 275 ng/dL, and post-hoc analyses confirm greater lean mass gains in the subgroup with testosterone below 200 ng/dL.

BMI above 27 kg/m2. Visceral adiposity amplifies the hypogonadal metabolic phenotype and also provides more substrate for the fat oxidation shift. Men with BMI <27 at baseline show smaller fat mass reductions, though lean mass gains are similar. See PMID 24951287 for CT visceral fat data supporting this stratification.

Age 40 to 65. Older men (above 65, as in the T-Trials) show meaningful but somewhat attenuated mitochondrial responses compared with middle-aged hypogonadal men, possibly reflecting age-related decline in satellite cell responsiveness.

Concurrent resistance training. Testosterone's anabolic effects on lean mass are additive with resistance training, not substitutive. A 1996 NEJM trial by Bhasin et al. (N=43) showed that testosterone plus exercise produced 6.1 kg of lean mass gain at 10 weeks, versus 3.2 kg with testosterone alone, 1.9 kg with exercise alone, and 0.8 kg with placebo. PMID 8637535.